A fine line between failure and success
It’s time for a look at some important Gems from the Poster Halls.
In part 1 of this series, we take a look at some targets where companies have struggled in the past and look at them afresh with new or next generation agents coming down the pike. Where possible we also explain why these compounds might succeed where their earlier competitors did not.
Fond memories of the ASH poster hall in the translational sections before the evening rugby scrum!
What’s in store? In the latest review, some of these compounds are more selective or have improved potency, others take the form of a different modality or formulation, and so on.
Not all compounds are the same, after all, and sometimes choosing an alternative dosing strategy or combination partner can make all the difference between success and failure, as can different PK/PD properties.
A few tweaks here and there and the line between these two extremes is often finer than many outsiders realise.
The second review will follow early in the New Year after the Holidays and highlight completely different targets and agents of interest.
In the meantime, in the first installment here’s nine gems from the ASH poster halls to contemplate…
BSB subscribers can read up on our ongoing commentary and analysis from the ASH annual meeting – you can either log-in or click to access the back story behind the latest innovations.
This content is restricted to subscribers
